GLP-1 MEDICATIONS AND THE GUT
What you need to know. GLP-1 receptor agonists, including semaglutide and dulaglutide, are increasingly used for type 2 diabetes and weight management. Their effects on appetite, gastric emptying and...
Read more...
What you need to know. GLP-1 receptor agonists, including semaglutide and dulaglutide, are increasingly used for type 2 diabetes and weight management. Their effects on appetite, gastric emptying and...
Read more...
Online CRC Screening & Surveillance Decision-Support Tools GPs play a crucial role in colorectal cancer prevention, but CRC screening and surveillance guidelines are often complex, detailed, and...
Read more...
My patient has tried Movicol, fibre and stimulant laxatives. What’s next? Chronic constipation is a very common presentation in general practice. First line therapy typically includes dietary...
Read more...
Bloating, a benign nuisance or a red flag? Bloating and abdominal distension are common in general practice and are often functional. They are frequently associated with under-recognised...
Read more...
Helicobacter pylori (H.Pylori) eradication reduces the risk of peptic ulcer recurrence, gastric cancer, and persistent dyspepsia. In Australia, the most commonly used first-line regimen...
Read more...
What you need to know. Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as NAFLD, is now the most common chronic liver condition worldwide. It is strongly associated...
Read more...
Metabolic dysfunction-associated steatotic liver disease (MASLD) or Metabolic-associated fatty liver disease (MAFLD), has become the most common chronic liver disease, and its prevalence will likely...
Read more...
Intestinal ultrasound (IUS) is an accurate and non-invasive tool to assess disease activity in inflammatory bowel disease (IBD). IUS is now increasingly used in Australia as a method to monitor...
Read more...